Search

MSK award recognizes promising investigators for their efforts in advancing cancer research.

… Tuesday, November 12, 2019 Nathanael Gray, Joshua Mendell, and Christopher Vakoc (From left) Nathanael Gray, Joshua Mendell, and Christopher Vakoc are the three recipients of the 2019 Paul Marks Prize for Cancer Research. Memorial Sloan Kettering (MSK) has named three investigators as the recipients

A collaborative effort among cancer experts from Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College has yielded an interesting association: Obesity prior to diagnosis is associated with a five-fold increase in the risk of death from early-stage squamous cell carcinoma of the tongue.

… Tuesday, February 4, 2014 Cancer experts from Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College are working side by side to unravel the mysterious link between obesity and cancer. Most recently, their collaborative effort has yielded an interesting association: Obesity prior to

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Friday, February 19, 2021 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Three MSK Experts Named to New Class of American Academy of Microbiology Fellows Esther Babady, Kenneth Marians, and Tobias Hohl Esther Babady, PhD, D(ABMM), FIDSA , Clinical Microbiology

A new study by researchers at Memorial Sloan Kettering Cancer Center reveals the genetic underpinnings of what causes lung cancer to quickly metastasize, or spread, to the brain and the bone - the two most prominent sites of lung cancer relapse.

… Thursday, July 2, 2009 A new study by researchers at Memorial Sloan Kettering Cancer Center (MSKCC) reveals the genetic underpinnings of what causes lung cancer to quickly metastasize, or spread, to the brain and the bone - the two most prominent sites of lung cancer relapse. The study will be published

A new multi-center study shows that an experimental drug lowers prostate specific antigen (PSA) levels - a marker for tumor growth - in men with advanced prostate cancer for whom traditional treatment options have failed.

… Thursday, April 9, 2009 A new multi-center study shows that an experimental drug lowers prostate specific antigen (PSA) levels - a marker for tumor growth - in men with advanced prostate cancer for whom traditional treatment options have failed. The study, led by researchers at Memorial Sloan Kettering

Learn why a new finding suggests that men with advanced prostate cancer should be screened for gene mutations.

… Wednesday, July 6, 2016 Summary Inherited mutations in DNA-repair genes, such as the BRCA genes , can increase cancer risk. A new study shows that DNA-repair mutations are significantly more common in men with metastatic prostate cancer compared with men whose prostate cancer hasn’t spread. This suggests

Methods to generate stem cells have given scientists new ways to study some diseases and identify potential drugs, and could one day be used to rebuild diseased or damaged tissues in patients.

… Tuesday, December 11, 2012 Summary Methods to generate stem cells have given scientists new ways to study some diseases and identify potential drugs, and could one day be used to rebuild diseased or damaged tissues in patients. On December 10, John B. Gurdon of the University of Cambridge and Shinya

Understanding tumor heterogeneity may be the next big quest in cancer science, as differences between cells within a tumor can have important consequences for how cancers are diagnosed and treated.

… Wednesday, July 2, 2014 Summary Understanding tumor heterogeneity may be the next big quest in cancer science, as differences between cells within a tumor can have important consequences for how cancers are diagnosed and treated. Every person’s cancer develops and grows in its own way and is unique in

In honor of Women's History Month, meet the scientific hero who helped build MSK's molecular biology program.

… Wednesday, March 13, 2019 Ora Rosen Ora Rosen, an expert in insulin signaling, co-founded the Molecular Biology Program at the Sloan Kettering Institute. Ora Rosen Dr. Rosen (right) with graduate students Roman Herrera and Lilli Petruzzelli Summary In honor of Women’s History Month, we’re remembering

Patients with a rare but aggressive form of cancer now have access to a drug that has proven effective after the disease becomes resistant to standard treatments.

… Tuesday, December 1, 2009 Summary Patients with a rare but aggressive form of cancer now have access to a drug that has proven effective after the disease becomes resistant to standard treatments. Patients with a rare but aggressive form of cancer now have access to a drug that has proven effective after